| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Gene
Departments of Medicine (M.H., A.Q., K.K.B., N.J.C., D.A.E.), Biochemistry and Molecular Biology (S.Y.A.), and Human Genetics (N.J.C.), University of Chicago, Chicago, Illinois 60637
Address all correspondence and requests for reprints to: David A. Ehrmann, M.D., Department of Medicine, Section of Endocrinology, University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, MC 1027, Chicago, Illinois 60637. E-mail: dehrmann{at}medicine.bsd.uchicago.edu
Abstract
Polycystic ovary syndrome (PCOS) is common in women of reproductive age and is associated with a high risk for development of type 2 diabetes. Insulin resistance, a key component in the pathogenesis of PCOS and glucose intolerance, is ameliorated by the thiazolidinediones, synthetic ligands for the PPAR
. In the present study we have examined the relationship of the Pro12Ala polymorphism in the PPAR
gene (PPARG) to clinical and hormonal features of PCOS.
Two hundred and eighteen women with PCOS had a 75-g oral glucose tolerance test, and blood was obtained for measurement of serum androgen levels. Sixty percent of the subjects were Caucasian, 26% were African-American, 6% were Hispanic, 6% were South Asian, and 2% were Middle-Eastern. Compared with Caucasians, the African-American group had a higher prevalence of diabetes (19% vs. 5%, respectively), were more obese (body mass index, 40.9 ± 1.8 vs. 36.3 ± 0.8 kg/m2; P < 0.05), and were more insulin resistant.
Twenty-eight of 218 subjects had the Ala allele, all in the heterozygous state. The frequency of the Ala allele varied among the groups: 0.01 in African-Americans, 0.08 in Caucasians, and 0.15 in Hispanics. Nondiabetic Caucasians with an Ala allele (Pro/Ala group) were more insulin sensitive than those in the Pro/Pro group, as evidenced by a lower homeostasis model assessment index (5.18 ± 1.33 vs. 6.54 ± 0.54; P < 0.05) and lower levels of insulin at both the fasting (132 ± 27 vs. 165 ± 12 pmol/liter; P = 0.03) and 2 h (688 ± 103 vs. 10190 ± 99 pmol/liter; P = 0.04) time points during the oral glucose tolerance test. We conclude that Pro12Ala in PPARG is a modifier of insulin resistance in Caucasian women with PCOS.
This article has been cited by other articles:
![]() |
M. Simoni, C.B. Tempfer, B. Destenaves, and B.C.J.M. Fauser Functional genetic polymorphisms and female reproductive disorders: Part I: polycystic ovary syndrome and ovarian response Hum. Reprod. Update, July 4, 2008; (2008) dmn024v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Diamanti-Kandarakis and C. Piperi Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth Hum. Reprod. Update, November 1, 2005; 11(6): 631 - 643. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Azziz, C. Marin, L. Hoq, E. Badamgarav, and P. Song Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4650 - 4658. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Ruiz-Narvaez Is the Ala12 variant of the PPARG gene an "unthrifty allele"? J. Med. Genet., July 1, 2005; 42(7): 547 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.C. Tok, A. Aktas, D. Ertunc, E.M. Erdal, and S. Dilek Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-{gamma}2 Pro12Ala genotype Hum. Reprod., June 1, 2005; 20(6): 1590 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome Endocr. Rev., April 1, 2005; 26(2): 251 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Ehrmann, K. Kasza, R. Azziz, R. S. Legro, M. N. Ghazzi, and for the PCOS/Troglitazone Study Group Effects of Race and Family History of Type 2 Diabetes on Metabolic Status of Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 66 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Jansen, J. S. E. Laven, H. B. R. Dommerholt, J. Polman, C. van Rijt, C. van den Hurk, J. Westland, S. Mosselman, and B. C. J. M. Fauser Abnormal Gene Expression Profiles in Human Ovaries from Polycystic Ovary Syndrome Patients Mol. Endocrinol., December 1, 2004; 18(12): 3050 - 3063. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Orio Jr., S. Palomba, T. Cascella, S. Di Biase, D. Labella, T. Russo, S. Savastano, F. Zullo, A. Colao, R. Vettor, et al. Lack of an Association between Peroxisome Proliferator-Activated Receptor-{gamma} Gene Pro12Ala Polymorphism and Adiponectin Levels in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5110 - 5115. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Z. Al-Shali, A. A. House, A. J.G. Hanley, H. M.R. Khan, S. B. Harris, B. Zinman, M. Mamakeesick, A. Fenster, J. D. Spence, and R. A. Hegele Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor {gamma} Associated With Carotid Atherosclerosis Stroke, September 1, 2004; 35(9): 2036 - 2040. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. San Millan, M. Corton, G. Villuendas, J. Sancho, B. Peral, and H. F. Escobar-Morreale Association of the Polycystic Ovary Syndrome with Genomic Variants Related to Insulin Resistance, Type 2 Diabetes Mellitus, and Obesity J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2640 - 2646. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Orio Jr., G. Matarese, S. Di Biase, S. Palomba, D. Labella, V. Sanna, S. Savastano, F. Zullo, A. Colao, and G. Lombardi Exon 6 and 2 Peroxisome Proliferator-Activated Receptor-{gamma} Polymorphisms in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5887 - 5892. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Korhonen, S. Heinonen, M. Hiltunen, S. Helisalmi, M. Hippelainen, R. Koivunen, J.S. Tapanainen, and M. Laakso Polymorphism in the peroxisome proliferator-activated receptor-{gamma} gene in women with polycystic ovary syndrome Hum. Reprod., March 1, 2003; 18(3): 540 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Jaquet, D. A. Tregouet, T. Godefroy, V. Nicaud, D. Chevenne, L. Tiret, P. Czernichow, and C. Levy-Marchal Combined Effects of Genetic and Environmental Factors on Insulin Resistance Associated With Reduced Fetal Growth Diabetes, December 1, 2002; 51(12): 3473 - 3478. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Ehrmann, X. Tang, I. Yoshiuchi, N. J. Cox, and G. I. Bell Relationship of Insulin Receptor Substrate-1 and -2 Genotypes to Phenotypic Features of Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4297 - 4300. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Ehrmann, P. E. H. Schwarz, M. Hara, X. Tang, Y. Horikawa, J. Imperial, G. I. Bell, and N. J. Cox Relationship of Calpain-10 Genotype to Phenotypic Features of Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1669 - 1673. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |